General
Preferred name
VARESPLADIB
Synonyms
LY-315920 ()
LY315920 ()
LY315920 (Varespladib) ()
LY315920(Varespladib) ()
Varespladib (LY315920) ()
VARESPLADIB SODIUM ()
Varepladib ()
P&D ID
PD011132
CAS
172732-68-2
Tags
available
drug candidate
Drug Status
investigational
Max Phase
2.0
Drug indication
Coronary artery disease
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively[1].
PRICE 119
DESCRIPTION Varespladib (LY315920) is a secretory phospholipase A2 (sPLA2) inhibitor in clinical development. The administered form can be varespladib sodium (A-001, for intravenuous administration) or varespladib methyl (A-002, for oral administration). The history of varespladib's discovery and development is summarized in . (GtoPdb)
DESCRIPTION Varespladib is a potent and selective group IIA, secretory phospholipase A2 inhibitor. It has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome. (Enamine Bioactive Compounds)
DESCRIPTION Varespladib is a potent and selective inhibitor of secretory phospholipase A2 (sPLA2). The compound Varespladib inhibits both human and mouse sPLA2 group IIA, V, and X enzymes at low nM concentrations. (BOC Sciences Bioactive Compounds)
DESCRIPTION Varespladib (LY315920), a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome. (TargetMol Bioactive Compound Library)
Compound Sets
17
AdooQ Bioactive Compound Library
A10548
BOC Sciences Bioactive Compounds
varespladib-cas-172732-68-2-item-84-417834
Cayman Chemical Bioactives
18267
ChEMBL Drugs
CHEMBL148674
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB11909
DrugMatrix
Enamine Bioactive Compounds
EBC-11288
Guide to Pharmacology
9657
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL148674
Mcule NIBR MoA Box Subset
MCULE-8968455753
MedChem Express Bioactive Compound Library
HY-13402
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
LY315920(Varespladib)
TargetMol Bioactive Compound Library
T2044
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
380.14
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
2.38
TPSA
111.62
Fraction CSP3
0.19
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
hnsPLA2
Phospholipase
PLA2G2A
Phospholipase (e.g. PLA)
Member status
member
MOA
Secretory Phospholipase A2 (sPLA2) Inhibitors
secretory phospholipase inhibitor
Pathway
Metabolic Enzyme/Protease
Metabolism
Source data